GPCR vs. NAMS, SDGR, SNDX, HRMY, CPRX, AMRX, AVDL, RNA, AGIO, and SUPN
Should you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include NewAmsterdam Pharma (NAMS), Schrödinger (SDGR), Syndax Pharmaceuticals (SNDX), Harmony Biosciences (HRMY), Catalyst Pharmaceuticals (CPRX), Amneal Pharmaceuticals (AMRX), Avadel Pharmaceuticals (AVDL), Avidity Biosciences (RNA), Agios Pharmaceuticals (AGIO), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceutical preparations" industry.
NewAmsterdam Pharma (NASDAQ:NAMS) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, community ranking, dividends, analyst recommendations, institutional ownership and media sentiment.
Structure Therapeutics has lower revenue, but higher earnings than NewAmsterdam Pharma.
Structure Therapeutics received 2 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 76.47% of users gave Structure Therapeutics an outperform vote.
89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 2.5% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Structure Therapeutics' return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.
In the previous week, Structure Therapeutics had 6 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 8 mentions for Structure Therapeutics and 2 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.78 beat Structure Therapeutics' score of 0.53 indicating that Structure Therapeutics is being referred to more favorably in the news media.
NewAmsterdam Pharma presently has a consensus target price of $33.25, suggesting a potential upside of 50.45%. Structure Therapeutics has a consensus target price of $85.71, suggesting a potential upside of 138.29%. Given NewAmsterdam Pharma's higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than NewAmsterdam Pharma.
Summary
Structure Therapeutics beats NewAmsterdam Pharma on 7 of the 12 factors compared between the two stocks.
Get Structure Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Structure Therapeutics Competitors List
Related Companies and Tools
